
MannKind Corporation (NASDAQ:MNKD) on Monday agreed to acquire scPharmaceuticals Inc. (NASDAQ:SCPH) for a deal value of up to approximately $360 million, or $5.35 per share.
The deal marks MannKind’s strategic expansion into cardiorenal medicine, establishing its cardiometabolic business alongside its orphan lung division. It is also made possible on the heels of MannKind’s $500 million strategic financing agreement with Blackstone.